Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9NY30
UPID:
BTG4_HUMAN
Alternative names:
BTG family member 4; Protein PC3b
Alternative UPACC:
Q9NY30; Q8NEH7
Background:
Protein BTG4, also known as BTG family member 4 or Protein PC3b, plays a pivotal role in early embryonic development. It acts as an adapter protein, linking CNOT7, a component of the CCR4-NOT complex, to EIF4E. This interaction is crucial for the decay of maternal mRNAs during oocyte maturation and after fertilization, facilitating the maternal-zygotic transition, zygotic cleavage, and the onset of embryogenesis.
Therapeutic significance:
Protein BTG4's involvement in oocyte/zygote/embryo maturation arrest 8, an autosomal recessive infertility disorder, underscores its therapeutic potential. Understanding the role of Protein BTG4 could open doors to potential therapeutic strategies for treating infertility issues related to early embryonic development failures.